Given that FAK is overexpressed in multiple primary solid tumors, and even more in invasive and metastatic cancers (Sulzmaier et al, 2014; Weiner et al, 1993), understanding the mechanisms of FAK inhibitor resistance is of paramount clinical importance. Here, PTK2 is linked to metastatic malignant neoplasm.